These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Conference updates show promising drug data. AIDS Alert; 1997 Nov; 12(11):125-6. PubMed ID: 11364769 [Abstract] [Full Text] [Related]
25. ACTG 343: three drugs better than two for maintaining HIV suppression. Bowersox J. NIAID AIDS Agenda; 1998 Mar; ():1-2, 10-1. PubMed ID: 11365088 [Abstract] [Full Text] [Related]
29. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, Stryker R, Johnson P, Labriola DF, Farina D, Manion DJ, Ruiz NM. N Engl J Med; 1999 Dec 16; 341(25):1865-73. PubMed ID: 10601505 [Abstract] [Full Text] [Related]
30. Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA. Rizzardi GP, De Boer RJ, Hoover S, Tambussi G, Chapuis A, Halkic N, Bart PA, Miller V, Staszewski S, Notermans DW, Perrin L, Fox CH, Lange JM, Lazzarin A, Pantaleo G. J Clin Invest; 2000 Mar 16; 105(6):777-82. PubMed ID: 10727446 [Abstract] [Full Text] [Related]
33. Protease inhibitors at a glance... Notes Undergr; 2000 Mar 16; (No 38):suppl 1-4. PubMed ID: 11366198 [Abstract] [Full Text] [Related]
34. Drug combination shows benefits for AIDS patients with history of taking AZT. AIDS Patient Care STDS; 1996 Jun 16; 10(3):185-6. PubMed ID: 11361628 [No Abstract] [Full Text] [Related]
35. Protease inhibitor combos. Newsline People AIDS Coalit N Y; 1998 Feb 16; ():36-7. PubMed ID: 11367448 [Abstract] [Full Text] [Related]
36. Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial. Matheron S, Descamps D, Boué F, Livrozet JM, Lafeuillade A, Aquilina C, Troisvallets D, Goetschel A, Brun-Vezinet F, Mamet JP, Thiaux C, CNA3007 Study Group. Antivir Ther; 2003 Apr 16; 8(2):163-71. PubMed ID: 12741629 [Abstract] [Full Text] [Related]
37. Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study. Wolbers M, Opravil M, von Wyl V, Hirschel B, Furrer H, Cavassini M, Vernazza P, Bernasconi E, Battegay M, Yerly S, Günthard H, Bucher HC, Swiss HIV Cohort Study. AIDS; 2007 Oct 18; 21(16):2201-7. PubMed ID: 18090047 [Abstract] [Full Text] [Related]
38. Focusing on the second phase of plasma HIV-1 RNA clearance. Lafeuillade A, Poggi C, Sayada C, Pellegrino P, Profizi N. AIDS; 1997 Feb 18; 11(2):264-6. PubMed ID: 9030385 [No Abstract] [Full Text] [Related]
39. Nelfinavir - major trial results at retroviruses conference. AIDS Treat News; 1997 Feb 21; (No 265):3-4. PubMed ID: 11364240 [Abstract] [Full Text] [Related]
40. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients. Idoko JA, Akinsete L, Abalaka AD, Keshinro LB, Dutse L, Onyenekwe B, Lhekwaba A, Njoku OS, Kehinde MO, Wambebe CO. West Afr J Med; 2002 Feb 21; 21(2):83-6. PubMed ID: 12403023 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]